Area of research
Otorhinolaryngology · Surgery
Research interest
Research focused on Cancer research and Metastasis, with related work in Angiogenesis, Downregulation and upregulation, Gene knockdown. Notable publications include 'Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer', 'Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway', and 'MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFβR1/Smad signaling pathway in NSCLC'.
Tumor suppressor KEAP1 promotes HSPA9 degradation, controlling mitochondrial biogenesis in breast cancer
An antihypertensive drug-AT1 inhibitor attenuated BRCA development promoted by chronic psychological stress via Ang II/PARP1/FN1 pathway
Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial
PLEASURABLE: Results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC).
The metastasis patterns and their prognostic features in patients with de novo metastatic breast cancer of different ages
USF1-ATRAP-PBX3 Axis Promote Breast Cancer Glycolysis and Malignant Phenotype by Activating AKT/mTOR Signaling
Systematic analysis of the expression and prognostic value of ITPR1 and correlation with tumor infiltrating immune cells in breast cancer
Survival analysis and nomogram for early-stage occult breast cancer with positive lymph nodes based on the SEER database
Feasibility of ipsilateral elective neck irradiation of levels Ib and <scp>II</scp> without level <scp>III</scp> in patients with node‐negative sinonasal squamous cell carcinoma
Author Correction: MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFβR1/Smad signaling pathway in NSCLC
Apatinib plus etoposide as second-or higher-line treatment in recurrent or metastatic triple-negative breast cancer: A single-arm, open label, prospective, phase II clinical trial.
GABARAP suppresses EMT and breast cancer progression via the AKT/mTOR signaling pathway
Radiosensitizing effect of gold nanoparticle loaded with small interfering RNA-SP1 on lung cancer
Comprehensive landscape of the renin-angiotensin system in Pan-cancer: a potential downstream mediated mechanism of SARS-CoV-2
Two‐pore channels regulate Tat endolysosome escape and Tat‐mediated HIV‐1 LTR transactivation
Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis
USP22 promotes development of lung adenocarcinoma through ubiquitination and immunosuppression
Targeting 14-3-3ζ Overcomes Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma via BMP2/Smad/ID1 Signaling
Targeting 14-3-3ζ overcomes resistance to EGFR-TKI in lung adenocarcinoma via BMP2/Smad/ID-1 signaling
GABARAP suppresses EMT and breast cancer progression via the AKT/mTOR signaling pathway
Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway
Role of endolysosomes and pH in the pathogenesis and treatment of glioblastoma
Expression of ASPH protein in retroperitoneal liposarcoma and its clinical significances
USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma
The microRNA miR-181c enhances chemosensitivity and reduces chemoresistance in breast cancer cells via down-regulating osteopontin
Overexpression of 14‑3‑3ζ in lung tissue predicts an improved outcome in patients with lung adenocarcinoma
TRIM44 promotes proliferation and metastasis in non-small cell lung cancer via mTOR signaling pathway
miRNA-378 reverses chemoresistance to cisplatin in lung adenocarcinoma cells by targeting secreted clusterin
EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations
FAT10 is associated with the malignancy and drug resistance of non-small cell lung cancer